Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L; NIAID HIV Vaccine Trials Network.

Vaccine. 2011 Feb 24;29(10):1948-58. doi: 10.1016/j.vaccine.2010.12.104. Epub 2011 Jan 7.

2.

DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.

Manrique M, Micewicz E, Kozlowski PA, Wang SW, Aurora D, Wilson RL, Ghebremichael M, Mazzara G, Montefiori D, Carville A, Mansfield KG, Aldovini A.

AIDS Res Hum Retroviruses. 2008 Mar;24(3):505-19. doi: 10.1089/aid.2007.0191.

3.

Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors.

Santra S, Sun Y, Parvani JG, Philippon V, Wyand MS, Manson K, Gomez-Yafal A, Mazzara G, Panicali D, Markham PD, Montefiori DC, Letvin NL.

J Virol. 2007 Aug;81(16):8563-70. Epub 2007 Jun 6.

4.

Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.

Jackson SS, Ilyinskii P, Philippon V, Gritz L, Yafal AG, Zinnack K, Beaudry KR, Manson KH, Lifton MA, Kuroda MJ, Letvin NL, Mazzara GP, Panicali DL.

J Virol. 2005 May;79(10):6554-9.

5.

Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.

Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, Gritz L, Yafal AG, Ogueta S, Greenhalgh P, Manson K, Panicali D, Schlom J.

Clin Cancer Res. 2005 Feb 15;11(4):1597-607.

6.

Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting.

Peacock JW, Nordone SK, Jackson SS, Liao HX, Letvin NL, Yafal AG, Gritz L, Mazzara GP, Haynes BF, Staats HF.

J Virol. 2004 Dec;78(23):13163-72.

7.

An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.

Wang SW, Bertley FM, Kozlowski PA, Herrmann L, Manson K, Mazzara G, Piatak M, Johnson RP, Carville A, Mansfield K, Aldovini A.

AIDS Res Hum Retroviruses. 2004 Aug;20(8):846-59.

PMID:
15320989
8.

Brain tumor target volume determination for radiation treatment planning through automated MRI segmentation.

Mazzara GP, Velthuizen RP, Pearlman JL, Greenberg HM, Wagner H.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):300-12.

PMID:
15093927
9.

Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.

Bertley FM, Kozlowski PA, Wang SW, Chappelle J, Patel J, Sonuyi O, Mazzara G, Montefiori D, Carville A, Mansfield KG, Aldovini A.

J Immunol. 2004 Mar 15;172(6):3745-57.

10.

Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC.

Atanackovic D, Matsuo M, Ritter E, Mazzara G, Ritter G, Jäger E, Knuth A, Old LJ, Gnjatic S.

J Immunol Methods. 2003 Jul;278(1-2):57-66.

PMID:
12957396
11.

Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251.

Radaelli A, Nacsa J, Tsai WP, Edghill-Smith Y, Zanotto C, Elli V, Venzon D, Tryniszewska E, Markham P, Mazzara GP, Panicali D, De Giuli Morghen C, Franchini G.

Virology. 2003 Jul 20;312(1):181-95.

12.

Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system.

Evans DT, Chen LM, Gillis J, Lin KC, Harty B, Mazzara GP, Donis RO, Mansfield KG, Lifson JD, Desrosiers RC, Galán JE, Johnson RP.

J Virol. 2003 Feb;77(4):2400-9.

14.

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals.

Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A, Brander C, Robbins GK, Mazzara GP, Goulder PJ, Walker BD; HIV Controller Study Collaboration.

Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1781-6.

15.

Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

Gnjatic S, Nagata Y, Jager E, Stockert E, Shankara S, Roberts BL, Mazzara GP, Lee SY, Dunbar PR, Dupont B, Cerundolo V, Ritter G, Chen YT, Knuth A, Old LJ.

Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10917-22.

16.

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW.

Clin Cancer Res. 2000 May;6(5):1632-8.

17.
18.

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations.

Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, Rizvi TA, Lu S, Hu SL, Mazzara GP, Panicali DL, Herndon JG, Glickman R, Candido MA, Lydy SL, Wyand MS, McClure HM.

Nat Med. 1999 May;5(5):526-34.

PMID:
10229229
19.

The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation.

Kalus RM, Kantor JA, Gritz L, Gómez Yafal A, Mazzara GP, Schlom J, Hodge JW.

Vaccine. 1999 Feb 26;17(7-8):893-903.

PMID:
10067696
20.

Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.

Wilson SE, Pedersen SL, Kunich JC, Wilkins VL, Mann DL, Mazzara GP, Tartaglia J, Celum CL, Sheppard HW.

AIDS Res Hum Retroviruses. 1998 Jul 20;14(11):925-37.

PMID:
9686639
21.

Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity.

Kim CJ, Cormier J, Roden M, Gritz L, Mazzara GP, Fetsch P, Hijazi Y, Lee KH, Rosenberg SA, Marincola FM.

Ann Surg Oncol. 1998 Jan-Feb;5(1):64-76.

PMID:
9524710
22.

Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development.

Cao H, Kanki P, Sankalé JL, Dieng-Sarr A, Mazzara GP, Kalams SA, Korber B, Mboup S, Walker BD.

J Virol. 1997 Nov;71(11):8615-23.

23.

Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7.

Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA.

J Immunother. 1997 Jan;20(1):38-47.

PMID:
9101412
24.

Use of a modified polysaccharide gel in developing a realistic breast phantom for MRI.

Mazzara GP, Briggs RW, Wu Z, Steinbach BG.

Magn Reson Imaging. 1996;14(6):639-48.

PMID:
8897368
25.
26.

Contribution of hypervariable domains to the conformation of a broadly neutralizing glycoprotein 120 epitope.

Lee CN, Robinson J, Mazzara G, Cheng YL, Essex M, Lee TH.

AIDS Res Hum Retroviruses. 1995 Jul;11(7):777-81.

PMID:
7546903
27.

High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection.

Daniel MD, Mazzara GP, Simon MA, Sehgal PK, Kodama T, Panicali DL, Desrosiers RC.

AIDS Res Hum Retroviruses. 1994 Jul;10(7):839-51.

PMID:
7986589
28.

High dielectric permittivity of ceramic and single-crystal PrBa2Cu3Ox.

Mazzara GP, Skirius S, Cao G, Chern G, Clark RJ, Crow JE, Mathias H, O'Reilly JW, Testardi LR.

Phys Rev B Condens Matter. 1993 Apr 1;47(13):8119-8123. No abstract available.

PMID:
10004823
29.

Immunization with lentivirus-like particles elicits a potent SIV-specific recall cytotoxic T-lymphocyte response in rhesus monkeys.

Shen L, Mazzara GP, DiSciullo SO, Panicali DL, Letvin NL.

AIDS Res Hum Retroviruses. 1993 Feb;9(2):129-32.

PMID:
8384466
30.

Generation and analysis of vaccinia virus recombinants.

Mazzara GP, Destree A, Mahr A.

Methods Enzymol. 1993;217:557-81. No abstract available.

PMID:
8474351
31.

Use of lentivirus-like particles alone and in combination with live vaccinia-virus-based vaccines.

Panicali DL, Mazzara G, Sullivan JL, Hesselton R, Shen L, Letvin N, Daniel M, Desrosiers R, Stott EJ.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1449. No abstract available.

PMID:
1466979
34.

Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes.

Shen L, Chen ZW, Miller MD, Stallard V, Mazzara GP, Panicali DL, Letvin NL.

Science. 1991 Apr 19;252(5004):440-3.

PMID:
1708168
35.
36.

Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env.

Gritz L, Destree A, Cormier N, Day E, Stallard V, Caiazzo T, Mazzara G, Panicali D.

J Virol. 1990 Dec;64(12):5948-57.

37.

Two distinct lymphocyte populations mediate simian immunodeficiency virus envelope-specific target cell lysis.

Yamamoto H, Miller MD, Watkins DI, Snyder GB, Chase NE, Mazzara GP, Gritz L, Panicali DL, Letvin NL.

J Immunol. 1990 Dec 1;145(11):3740-6.

PMID:
2147200
38.

Studies of cloned simian immunodeficiency virus-specific T lymphocytes. gag-specific cytotoxic T lymphocytes exhibit a restricted epitope specificity.

Yamamoto H, Miller MD, Tsubota H, Watkins DI, Mazzara GP, Stallard V, Panicali DL, Aldovini A, Young RA, Letvin NL.

J Immunol. 1990 May 1;144(9):3385-91.

PMID:
1691757
39.

The gag-specific cytotoxic T lymphocytes in rhesus monkeys infected with the simian immunodeficiency virus of macaques.

Miller MD, Lord CI, Stallard V, Mazzara GP, Letvin NL.

J Immunol. 1990 Jan 1;144(1):122-8.

PMID:
2153161
40.

Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs.

Koup RA, Sullivan JL, Levine PH, Brettler D, Mahr A, Mazzara G, McKenzie S, Panicali D.

Blood. 1989 May 15;73(7):1909-14.

PMID:
2785419
41.

Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera.

Koup RA, Sullivan JL, Levine PH, Brewster F, Mahr A, Mazzara G, McKenzie S, Panicali D.

J Virol. 1989 Feb;63(2):584-90.

42.

Searching for clones with open reading frames.

Gray MR, Mazzara GP, Reddy P, Rosbash M.

Methods Enzymol. 1987;154:129-56. No abstract available.

PMID:
3431458
43.

Characterization of bacteriophage T4 and D RNA, a low-molecular-weight RNA of unknown function.

Plunkett G, Mazzara GP, McClain WH.

Arch Biochem Biophys. 1981 Aug;210(1):298-306. No abstract available.

PMID:
6271070
44.

DNA sequence of the transfer RNA region of bacteriophage T4: implications for transfer RNA synthesis.

Mazzara GP, Plunkett G 3rd, McClain WH.

Proc Natl Acad Sci U S A. 1981 Feb;78(2):889-92.

45.

Cysteine transfer RNA of Escherichia coli: nucleotide sequence and unusual metabolic properties of the 3' C-C-A terminus.

Mazzara GP, McClain WH.

J Mol Biol. 1977 Dec 25;117(4):1061-79. No abstract available.

PMID:
342705
46.

Nucleotide sequence of an arginine transfer ribonucleic acid from bacteriophage T4.

Mazzara GP, Seidman JG, McClain WH, Yesian H, Abelson J, Guthrie C.

J Biol Chem. 1977 Nov 25;252(22):8245-53.

Supplemental Content

Loading ...
Support Center